Molecular diagnostics company Genetic Technologies (NASDAQ: GENE) shares have rocketed premarket on Thursday after the company provided an update on its COVID-19 severity risk test saying its predictive capabilities improved 100% over age and sex alone.
Genetic stated that analysis confirmed the test is well-calibrated, and additional datasets will continue to enhance the accuracy and consistency of its algorithm.
The company anticipates submission for regulatory clearance via the Centers for Medicare and Medicaid Services/Clinical Laboratory Improvement Amendments (CLIA) by the end of the first quarter of 2021 after the final validation process of an expanded dataset.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
They are also in conversations on commercialisation opportunities in conjunction with CLIA regulatory submission and clearance.
Alongside the announcement, Genetic said it has begun equipment calibration along with specialized inhouse training of the scientific team to establish the Germline Testing division for hereditary cancer risk with the initial focus being on BRCA testing offered in conjunction with GeneType for Breast Cancer and Lynch Syndrome testing offered in conjunction with GeneType Colorectal Cancer.
Genetic shares initially jumped over 86% on the news and are currently trading at $7.74, +80%.
